Targovax to host Investor Event: Meet the Management on 27 September

2022 has been a very active year for Targovax and our sector, and we invite you to an Investor Event Tuesday 27 September 2022. DNB will provide an analyst’s view of the biotech industry followed by presentations from Targovax with a focus on circRNA. We will finish the event with an opportunity for you to speak with members of our management team in an informal setting with food and refreshments.

Targovax's management team will present in Norwegian and are available for questions during the social event.

Date: Tuesday 27 September
Time: 17.00-19.00
Location: Sentralen, Øvre Slottsgate 3, Oslo

  • An analyst's view of the biotech market
    • Dr. Geir Hiller Holom, Senior Equity Analyst at DNB Markets
  • Targovax Business Overview
    • Dr. Erik Digman Wiklund, CEO of Targovax
  • Circular RNA (circRNA) – the new frontier in RNA therapeutics discovered in Scandinavia
    • Dr. Thomas Hansen, VP Research at Targovax

There will be an informal Q&A and serving of food from 17:45.

Lubor Gaal, CFO og Andreas Storsve, VP Business Development, will also be present.

Registration by Monday 26 September at 12:00 to renate.birkeli@targovax.com

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Building on successful studies demonstrating clinical efficacy and providing deep mechanistic insights, the Targovax platform is being expanded into delivery of circular RNA (circRNA). In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, due to enter the clinic in the second half of 2022. This provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.